H.R. 10628
Changes when biosimilar drugs enter Medicare price talks
Alters when biosimilar biological products become eligible for price negotiations under the Medicare program.
- Changes the timing of eligibility for Medicare price negotiations
- Applies to biosimilar biological products
- Amends part of the Social Security Act that covers Medicare
In committee